| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Purixan | Purixan | 20mg | Chemotherapy | Antimetabolite | Purine | Yes | 2014 | In Use | |||
| NA | Avapritinib | Ayvakit | 300mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| NA | Erlotinib | Tarceva | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| Not yet assigned | Tisagenlecleucel | Kymriah | consult labeling | Immunotherapy | CAR-T | CD19 | No | 2017 | In Use | |||
| J2430 | Pamidronate disodium | Aredia | 30mg | Ancillary Therapy | Bisphosphonate | No | 1987 | In Use | ||||
| NA | Dasatinib | Sprycel | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
| NA | Estradiol | Estrace | 0.5mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
| NA | Toremifene Citrate | Fareston | 60 mg | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Yes | 1997 | In Use | ||||
| NA | Megestrol Acetate | Megace | 20mg, 40mg | Hormonal Therapy | Progestin | Yes | 1988 | In Use | ||||
| Capivasertib | Truqap | 160mg, 200mg | Chemotherapy | AKT Inhibitor | AKT 1/2/3 | Yes | 2023 | In Use | ||||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| N/A | Vepdegestrant | Veppanu | 100mg, 200mg | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Yes | 2026 | In Use | |||
| NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
| NA | Mesna | Mesnex | 400 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Yes | 2002 | In Use | |||
| Inovolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
| NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
| Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
| NA | Glasdegib | Daurismo | 25mg, 100mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2018 | In Use | |||
| NA | Thalidomide | Thalomid | 150 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| NA | Imatinib mesylate | Gleevec | 400 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | In Use | |||
| NA | Duvelisib | Copiktra | 15mg, 25mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2018 | In Use | |||
| N/A | Zidesamtinib | Jideytro | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, ALK, TRK | Yes | 2026 | In Use | |||
| NA | Darolutamide | Nubeqa | 300mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2019 | In Use | |||
| J0128 | Abarelix | Plenaxis | 10 mg | Hormonal Therapy | Androgen Receptor Inhibitor | LHRH antagonist | No | 2003 | 2005 | Jan 1, 2005 | No Longer Used | |
| NA | Enzalutamide | Xtandi | 40 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 2012 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home